The landscape of global human immunodeficiency virus (HIV) prevention is undergoing a critical transformation following a landmark agreement between biopharmaceutical giant Gilead Sciences and the Pan American Health Organization (PAHO). Announced in September 2026, the strategic collaboration is designed to drastically expedite access to Gilead’s revolutionary twice-yearly lenacapavir injection for pre-exposure prophylaxis (PrEP). By leveraging PAHO’s established Regional Revolving Funds, the partnership establishes a streamlined, centralized regional procurement pathway. This mechanism is engineered to bypass traditional administrative bottlenecks, ensuring that countries throughout Latin America and the Caribbean can secure timely, equitable access to an advanced long-acting biomedical prevention tool that promises to reshape public health interventions in high-burden regions.
The scope of the agreement encompasses 14 nations that fall outside the parameters of Gilead’s existing voluntary licensing agreements for generic drug manufacturing. Among the key beneficiaries are regional powerhouses and nations with distinct epidemiological challenges, including Argentina, Brazil, Chile, Ecuador, Mexico, Peru, Uruguay, and Venezuela. By introducing this supplementary procurement channel, Gilead and PAHO are effectively plugging crucial access gaps. This ensures that middle- and upper-middle-income countries in the Americas—which often fail to qualify for low-cost generic licensing frameworks reserved exclusively for low-income nations—can still acquire innovative, life-saving therapeutics at sustainable, consolidated public health prices.
The Urgency of Regional Intervention: Epidemiological Context in the Americas
To fully understand the gravity of the Gilead-PAHO partnership, one must examine the stark epidemiological trajectory of HIV across Latin America and the Caribbean over the past decade and a half. Public health data underscores a deeply concerning counter-trend in the region: while global infection rates have steadily declined due to expanded access to antiretroviral therapy (ART) and first-generation oral PrEP regimens, the Americas have moved in the opposite direction.
According to regional health surveillance reports, Latin America and the Caribbean witnessed an alarming 13% surge in new HIV infections between 2010 and 2024. This persistent upward trajectory has exposed systemic vulnerabilities in traditional prevention cascades. Daily oral PrEP—typically dependent on tenofovir disoproxil fumarate and emtricitabine—has proven highly effective in clinical trials. However, real-world implementation has been hampered by persistent adherence challenges. Daily pill fatigue, social stigma, structural inequities, and complex healthcare delivery models often lead to discontinuation, leaving vulnerable populations unprotected.
Long-acting injectable therapeutics like lenacapavir represent a paradigm shift in overcoming these behavioral and systemic barriers. By requiring administration only once every six months, the therapy significantly reduces the burden of compliance, offering a discreet and reliable alternative that can dramatically alter transmission dynamics among key populations, including men who have sex with men, transgender women, sex workers, and marginalized socioeconomic groups disproportionately affected by the epidemic.
Clinical Milestones and the Path to Regulatory Approval
The integration of lenacapavir into PAHO’s Regional Revolving Funds is underpinned by a robust body of clinical evidence, most notably the landmark PURPOSE clinical trial program. The PURPOSE 2 trial—a rigorous, global, late-stage clinical evaluation—assessed the safety, tolerability, and superior efficacy of twice-yearly subcutaneous lenacapavir as a PrEP option compared to background HIV incidence and standard daily oral interventions. The trial yielded overwhelmingly positive results, demonstrating near-complete protection against HIV acquisition and establishing a favorable safety profile that paved the way for accelerated regulatory submissions globally.
Prior to the PAHO collaboration, lenacapavir had already secured regulatory milestones in multiple international jurisdictions, where it is approved both for the treatment of multi-drug-resistant HIV in heavily treatment-experienced individuals and as an advanced prevention modality. The drug functions as a first-in-class capsid inhibitor, interfering with multiple essential stages of the HIV viral lifecycle, including capsid-mediated nuclear import of viral DNA, virus assembly and maturation, and capsid core stability. This unique mechanism of action ensures that cross-resistance with existing classes of antiretroviral therapies—such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase strand transfer inhibitors—is minimized.
Corporate and Institutional Leadership Perspectives
The formalization of the agreement elicited strong endorsements from leadership at both Gilead Sciences and PAHO, emphasizing a shared philosophy that scientific breakthroughs must be rapidly translated into tangible public health outcomes.
Johanna Mercier, Gilead Sciences Chief Commercial and Corporate Affairs Officer, underscored the strategic intent behind the partnership during the announcement. “The agreement between Gilead and PAHO reflects our shared commitment to help countries move as quickly as possible from scientific innovation to real-world access to HIV prevention and public health impact,” Mercier stated. She further elaborated on the foundational role of cross-sector cooperation in addressing global health crises: “For decades, Gilead has worked alongside governments, public health organisations and communities to expand access to HIV innovation around the world. These strategic partnerships are essential to our ambition to help end the HIV epidemic. This agreement demonstrates how collaboration can help accelerate access, support country-led implementation and create the conditions for sustainable scale.”
Public health experts and regional stakeholders have similarly lauded the initiative, noting that PAHO’s Regional Revolving Funds provide an unparallelled mechanism for pooled procurement. By aggregating demand across multiple member states, the Revolving Funds secure economies of scale, lower transactional costs, guarantee quality-assured product delivery, and protect participating nations from the volatile pricing structures often associated with fragmented pharmaceutical markets.
A Multi-Pronged Global Access Strategy
The collaboration with PAHO is not an isolated initiative; rather, it forms a cornerstone of Gilead’s broader, multifaceted global access strategy for lenacapavir. Recognizing that a single distribution model cannot address the diverse socio-economic realities of the 120-plus high-incidence, resource-constrained countries burdened by the HIV epidemic, Gilead has deployed a comprehensive portfolio of access interventions.
Beyond the PAHO agreement and traditional commercial channels, Gilead has previously established comprehensive voluntary licensing agreements with generic pharmaceutical manufacturers. These licenses permit qualified manufacturers to produce low-cost generic versions of lenacapavir for supply in low- and lower-middle-income countries, pending local regulatory approvals. Furthermore, the company is actively pursuing technology transfer initiatives to bolster regional manufacturing capacities.
Notably, as part of its expanding footprint in Latin America, Gilead is currently exploring collaborative frameworks to support local production capabilities in Brazil. This localized manufacturing strategy aims to foster sustainable health security, reduce supply chain vulnerabilities, and ensure long-term regional self-sufficiency in producing advanced biopharmaceuticals. These efforts run parallel to internal corporate investments in research and development infrastructure, highlighted by Gilead’s recent inauguration of a state-of-the-art 182,000-square-foot research facility at its corporate headquarters in Foster City, California, dedicated to accelerating the development of innovative medicines for complex and challenging human diseases.
Broader Socio-Economic and Public Health Implications
The introduction of lenacapavir into Latin America and the Caribbean via the PAHO framework carries profound implications for health economics, human rights, and regional epidemiology. From a pharmacoeconomic perspective, reducing HIV incidence rates through highly effective, long-acting prevention yields massive downstream savings for national healthcare systems. Treating chronic HIV infection requires a lifetime commitment to antiretroviral therapy, management of comorbid conditions, and hospitalization costs associated with advanced disease progression. Preventative interventions, by contrast, interrupt transmission chains before they take root, offering a high return on investment for Ministries of Health operating under constrained budgetary allocations.
Moreover, the psychological and social impacts of transitioning to a twice-yearly dosing schedule cannot be overstated. Biomedical interventions that alleviate the daily reminder of infection risk—and eliminate the need to conceal oral medication bottles from partners, family members, or employers—effectively dismantle deep-seated psychological and structural barriers to care. Confidentiality is preserved, stigma is mitigated, and marginalized individuals who previously avoided clinics due to fear of discrimination are more likely to engage with healthcare providers on a semi-annual basis.
Looking forward, the success of the Gilead-PAHO partnership will be measured not merely by the volume of doses procured, but by how effectively participating nations integrate lenacapavir into comprehensive, community-driven prevention packages. Successful implementation will require robust health worker training programs, continuous monitoring of drug adherence and resistance patterns, culturally tailored demand-generation campaigns, and equitable distribution networks that reach remote rural communities as effectively as urban centers.
As the 14 designated nations operationalize the agreement and prepare for national rollouts, the international public health community will watch closely. If the initiative succeeds in reversing the 13% infection surge documented across the Americas, the Gilead-PAHO model could well serve as a definitive blueprint for accelerating access to breakthrough biomedical innovations in other regions, bringing the global community measurably closer to the ultimate goal of ending the HIV epidemic.
